The quantum advantage: IP considerations for the next generation of life sciences innovation

As quantum-enabled innovation accelerates, patentability will hinge on predictability, disclosure, and modality-specific claim drafting in an increasingly unforgiving enablement landscape, explain Ray Miller and Joseph Wolfe of DLA Piper.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Kirkland subject of alleged conflict in trade secrets clash

19 May 2026 In the firm’s second IP conflict dispute in a year, a healthcare tech company claims Kirkland lawyers "committed the cardinal sin of trying to represent the conflicting interests of opposing parties".

Americas

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme

19 May 2026 The award could rise to several billions under federal antitrust law, after the pharma company was found to have engaged in anticompetitive conduct over constipation drug Amitiza.

Americas

AbbVie’s trade secret suit against a Chinese rival gets green light

18 May 2026 A US court has refused to throw out AbbVie's claim that a former scientist brought its cancer drug secrets to a Chinese rival.